Skip to main content

Generic Eraxis Availability

Last updated on Oct 6, 2021.

Eraxis is a brand name of anidulafungin, approved by the FDA in the following formulation(s):

ERAXIS (anidulafungin - powder;intravenous)

  • Manufacturer: VICURON HOLDINGS
    Approval date: February 17, 2006
    Strength(s): 50MG/VIAL [RLD]
  • Manufacturer: VICURON HOLDINGS
    Approval date: November 14, 2006
    Strength(s): 100MG/VIAL [RLD]

Has a generic version of Eraxis been approved?

No. There is currently no therapeutically equivalent version of Eraxis available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Eraxis. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Echinocandin pharmaceutical formulations containing micelle-forming surfactants
    Patent 6,960,564
    Issued: November 1, 2005
    Inventor(s): Milton; Nathaniel & Moder; Kenneth Philip & Sabatowski; James Lawrence & Sweetana; Stephanie Ann
    Assignee(s): Eli Lilly and Company

    Pharmaceutical formulations are described comprising an echinocandin compound or echinocandin/carbohydrate complex and a pharmaceutically acceptable micelle-forming surfactant in a non-toxic aqueous solvent such that the solubilization of the echinocandin compound is optimized and the ability to freeze-dry the solution is maintained. Both the solution and freeze-dried formulations have increased stability. A bulking agent, tonicity agent buffer and/or a stabilizing agent may optionally be added to the formulations to further enhance the stability of the formulation.

    Patent expiration dates:

    • April 12, 2021
      ✓ 
      Patent use: TREATMENT OF FUNGAL INFECTIONS
      ✓ 
      Drug product
  • Echinocandin pharmaceutical formulations containing micelle-forming surfactants
    Patent 7,709,444
    Issued: May 4, 2010
    Inventor(s): Milton; Nathaniel & Moder; Kenneth Philip & Sabatowski; James Lawrence & Sweetana; Stephanie Ann
    Assignee(s): Pfizer Inc.

    Pharmaceutical formulations are described comprising an echinocandin compound or echinocandin/carbohydrate complex and a pharmaceutically acceptable micelle-forming surfactant in a non-toxic aqueous solvent such that the solubilization of the echinocandin compound is optimized and the ability to freeze-dry the solution is maintained. Both the solution and freeze-dried formulations have increased stability. A bulking agent, tonicity agent buffer and/or a stabilizing agent may optionally be added to the formulations to further enhance the stability of the formulation.

    Patent expiration dates:

    • April 12, 2021
      ✓ 
      Patent use: TREATMENT OF FUNGAL INFECTIONS
      ✓ 
      Drug product

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:

    • September 22, 2023 - NEW PATIENT POPULATION

Glossary

Term Definition
Drug Patent A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.